Intermediate hepatocellular carcinoma
Conditions
Interventions
Sponsors
Henan cancer hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. patients who had a histologically or clinically confirmed diagnosis of HCC (according to the diagnostic criteria for primary liver cancer proposed by the Chinese Ministry of Health); 2. patients diagnosed with Barcelona Clinic Liver Cancer (BCLC) stage B HCC (4=9.0g/dlNeutrophils count>=1.5*10^9/Lplatelet count>=50*10^9/L; (2) serum ALB>=28g/L; TBIL<34.2µmol/LALTAST< 5-times the upper limit of the normal range or less; (3) BunCr<1.5-times the upper limit of the normal range or less; (4) INR<1.7 or Prothrombin time <4 s above the control.
Exclusion criteria
Exclusion criteria: 1. patient who was pregnant or breastfeeding; 2. Had main portal vein obstruction and/or vascular invasion (inferior vena cava, hepatic vein); 3. Biliary obstruction caused by tumor invasion; 4. Brain metastases; 5. Diffuse lesions or lesions with less blood supplyor boundary is not clear; 6. portosystemic shunt or hepatic arteriovenous fistula; 7. Tumor burden> 50%; 8. Congestive heart failure and / or uncontrolled high blood pressure; 9. Renal failure or renal insufficiency (requiring dialysis treatment); 10. HIV infection or severe active infection (except HBV / HCV); 11. Major surgery within 4weeks prior to the study entry, or a history of gastrointestinal hemorrhage; 12. Received molecularly targeted therapy within 4weeks prior to the study entry; 13. Combined with other malignancies (within 3 years); 14. Underwent systemic chemotherapy or TACE; 15. target lesions had received any treatment.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Time to progression;Disease control rate; | — |
Primary
| Measure | Time frame |
|---|---|
| Overall Survival time; | — |
Countries
China
Contacts
Public ContactHailiang Li
Outcome results
None listed